| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Sa | The Oral GLP-1 Tracker: Foundayo holds steady as Wegovy pill takes a 5% dip | ||
| Fr | Mapping psychedelics' commercial summit | ||
| Fr | Merck scores US, German wins over Halozyme in Keytruda Qlex patent fight | ||
| Fr | FDA sets up new safety council to keep tabs on approved vaccines, cell and gene therapies | ||
| Fr | Another 215 layoffs linked to Novo's New Jersey HQ | ||
| Fr | Fierce Pharma Asia-Ivonescimab's FDA snub; Pfizer's in vivo CAR-T deal; China fires scientists in fatal gene trial | ||
| Fr | Sanofi gets Genzyme asset across FDA finish line with key nod in Gaucher type 3 | ||
| Do | Facing down Dupixent cliff, Sanofi mulls buyout of Insmed and its blockbuster-to-be Brinsupri: Bloomberg | ||
| Do | Biogen unblurs life with Friedreich ataxia in patient-centered Skyclarys campaign | ||
| Do | Regeneron breaks into neurology with FDA nod in crowded myasthenia gravis | ||
| Do | Arcera strikes $1B+ pact to license Innogen's approved GLP-1 outside China | ||
| Do | Novartis CEO, staring down $16.7B post-2030 patent cliff, challenges Wall Street consensus | ||
| Do | J&J draws FDA rebuke for misstating Inlexzo's bladder-sparing benefits | ||
| Do | CDMO Lotte inks commercial production deal as work on South Korean plant wraps | ||
| Do | The GLP-1 Paradox: Strong Clinical Evidence, Weak Persistence Rates | ||
| Mi | BMS' ph. 3 Alzheimer's psychosis teaser builds confidence in Cobenfy expansion plan | ||
| Mi | AI's Real Prize: Building Tomorrow's CI Capability | ||
| Mi | Beren clinches long-awaited FDA nod for cyclodextrin drug in Niemann-Pick disease | ||
| Mi | FDA moves to yank Salerno's liquid cholesterol drug approval on missing reports | ||
| Mi | Novo expands DTC program Novocare to support Wegovy users through holistic health journey | ||
| Mi | Heidi Overton's FDA nomination pulled by White House: reports | ||
| Di | FDA's complete response letter for Summit's ivonescimab cites China-heavy data beyond survival miss | ||
| Di | GSK scores FDA approval for Nelkarmi, its 2nd lung cancer drug from Nuvalent deal | ||
| Di | Cosentyx bags FDA nod for 11th indication as Novartis looks to buffer 2029 patent cliff | ||
| Di | Viatris takes the wheel as Cadillac F1 team's new global pharma partner |